Abstracts tagged "Clinical Response"

Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Kim Hørslev-Petersen¹, Merete Lund Hetland², Peter Junker³, Jan Pødenphant⁴, Torkell Ellingsen⁵, Palle Ahlqvist⁶, Hanne M. Lindegaard⁷, Asta Linauskas⁸, Annette Schlemmer⁹, Mette Y. Dam¹⁰, Ib Hansen¹¹, Tine Lottenburger⁶, Anette Jørgensen¹², Sophine B. Krintel¹³, Johnny Raun¹⁴, Christian G. Ammitzbøll¹⁰, Julia Johansen¹³, Mikkel Østergaard¹⁵ and Kristian Stengaard-Pedersen¹⁰, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University at Gentofte, Hellerup, Denmark, ⁵Silkeborg Regional Hospital, Silkeborg, Denmark, ⁶University of Southern Denmark, Vejle, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Vendsyssel Hospital, Hjørring, Denmark, ⁹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Arhus University Hospital, Aarhus, Denmark, ¹¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹³Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁴University of Southern Denmark, Graasten, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…
Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Wendy White¹, Patricia Ryan², Xiang Guo³, Dominic Sinibaldi⁴, Gopi Ranganna⁵, Alex Godwood⁶, Didier Saurigny⁶, David Close⁶, Steve Eck⁴, Dee Wilkins¹, Lorin Roskos⁷, Matthew A. Sleeman⁸, Wanying Li⁹, Guy Cavet⁹ and Nadine A. Defranoux⁹, ¹Translational Sciences, MedImmune, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune LLC, Gaithersburg, MD, ⁴MedImmune, LLC, Gaithersburg, MD, ⁵Clinical Development, MedImmune, LLC, Cambridge, United Kingdom, ⁶MedImmune, Ltd, Cambridge, United Kingdom, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ⁹Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Rieke Alten¹, Robert Holt², Amy Grahn³, Patricia Rice⁴, Jeffery Kent², Frank Buttgereit⁵ and Allan Gibofsky⁶, ¹Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Medicine and Public Health, Hospital for Special Surgery, New York, NY
Background/Purpose: A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
Abstract Number: 2163 • 2013 ACR/ARHP Annual Meeting
Predictors Of No Improvement In Subjective Health Perception In Newly Diagnosed Rheumatoid Athritis Patients With a Good DAS28 Response At 12 Months In The Dutch Rheumatoid Arthritis Monitoring Tight Control Cohort
Martijn Oude Voshaar¹, Erik Taal², Peter M. ten Klooster³, Harald E. Vonkeman^2,4 and Mart A.F.J. van De Laar⁵, ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Psychology, Health and Technology, University of Twente, Enschede, Netherlands, ³Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Modern treatment strategies are highly successful in reducing disease activity in rheumatoid arthritis (RA). However, changes in clinical measures of disease activity may not…
Abstract Number: 1981 • 2013 ACR/ARHP Annual Meeting
Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis
Saad Feroz¹, Nicolino. Ruperto², Jiri Vencovsky³, Peter A. Lachenbruch¹, Brian Erman⁴, Adam Huber⁵, Brian M. Feldman⁶, Ingrid E. Lundberg⁷, Angela Pistorio⁸, Howard Rockette⁹, Frederick W. Miller¹, Rohit Aggarwal¹⁰, Lisa G. Rider¹, for The ACR-EULAR Myositis Response Criteria Project Group¹¹, Angelo Ravelli¹², Clarissa Pilkington¹³ and Sheila K. Oliveira¹⁴, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴SRA International, Research Triangle Park, NC, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸PRINTO, Genoa, Italy, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ¹³Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, ¹⁴Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].